Rhenman & Partners Asset Management Ab Gilead Sciences, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$840 Million
Q1 2025

A detailed history of Rhenman & Partners Asset Management Ab transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 233,500 shares of GILD stock, worth $25.2 Million. This represents 3.11% of its overall portfolio holdings.

Number of Shares

233,500

Previous 255,500 8.61%

Holding current value

$25.2 Million

Previous $23.6 Million 10.86%

% of portfolio

3.11%

Previous 2.46%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$89.14 - $117.41 $1.96 Million - $2.58 Million	-22,000 Reduced 8.61%	233,500 $26.2 Million
Q4 2024 Feb 13, 2025	SELL	$83.95 - $97.9 $9.32 Million - $10.9 Million	-111,000 Reduced 30.29%	255,500 $23.6 Million
Q3 2024 Nov 13, 2024	BUY	$66.59 - $83.99 $8.52 Million - $10.8 Million	128,000 Added 53.67%	366,500 $30.7 Million
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $7.04 Million - $8.13 Million	111,500 Added 87.8%	238,500 $16.4 Million
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $9.45 Million - $11.5 Million	-132,000 Reduced 50.97%	127,000 $9.3 Million
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $1.83 Million - $2.08 Million	25,000 Added 10.68%	259,000 $21 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $12.5 Million - $13.7 Million	169,500 Added 262.79%	234,000 $17.5 Million
Q3 2023 Nov 09, 2023	SELL	$73.94 - $80.67 $12.5 Million - $13.7 Million	-169,500 Reduced 72.44%	64,500 $4.83 Million
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $1.9 Million - $2.17 Million	-25,000 Reduced 9.65%	234,000 $18 Million
Q1 2023 May 11, 2023	SELL	$77.31 - $88.08 $850,410 - $968,880	-11,000 Reduced 4.07%	259,000 $21.5 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $4.17 Million - $4.76 Million	70,000 Added 35.0%	270,000 $21.2 Million
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $1.73 Million - $1.95 Million	30,000 Added 17.65%	200,000 $12.4 Million
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $6.08 Million - $7.62 Million	-105,000 Reduced 38.18%	170,000 $10.1 Million
Q4 2021 Feb 11, 2022	SELL	$64.88 - $73.64 $1.62 Million - $1.84 Million	-25,000 Reduced 8.33%	275,000 $20.2 Million
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $3.17 Million - $3.47 Million	-50,000 Reduced 14.29%	300,000 $20.7 Million
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $2.1 Million - $2.4 Million	-35,000 Reduced 9.09%	350,000 $22.6 Million
Q4 2020 Jan 19, 2021	BUY	$56.65 - $64.55 $5.38 Million - $6.13 Million	95,000 Added 32.76%	385,000 $22.4 Million
Q3 2020 Oct 13, 2020	BUY	$62.1 - $78.08 $3.73 Million - $4.68 Million	60,000 Added 26.09%	290,000 $18.3 Million
Q2 2020 Jul 16, 2020	BUY	$72.34 - $84.0 $16.6 Million - $19.3 Million	230,000 New	230,000 $17.7 Million
Q1 2019 Apr 11, 2019	SELL	$62.53 - $70.05 $11.8 Million - $13.2 Million	-188,200 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$60.54 - $79.0 $87,601 - $114,313	-1,447 Reduced 0.76%	188,200 $11.8 Million
Q3 2018 Oct 03, 2018	SELL	$71.28 - $78.92 $5.16 Million - $5.71 Million	-72,380 Reduced 27.62%	189,647 $14.6 Million
Q2 2018 Jul 20, 2018	BUY	$64.88 - $75.68 $1.62 Million - $1.89 Million	25,000 Added 10.55%	262,027 $18.6 Million
Q1 2018 Apr 11, 2018	SELL	$72.84 - $88.8 $3.55 Million - $4.33 Million	-48,724 Reduced 17.05%	237,027 $17.9 Million
Q4 2017 Jan 19, 2018	BUY	$71.15 - $83.52 $9.26 Million - $10.9 Million	130,200 Added 83.7%	285,751 $20.5 Million
Q3 2017 Oct 13, 2017	BUY	$72.11 - $85.47 $11.2 Million - $13.3 Million	155,551	155,551 $12.6 Million

Others Institutions Holding GILD

# of Institutions

2,288

Shares Held

997M

Call Options Held

9.62M

Put Options Held

10M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $135B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Gilead Sciences, Inc. Transaction History